BioCryst Pharmaceuticals (NASDAQ:BCRX) PT Raised to $15.00

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its target price hoisted by analysts at JMP Securities from $14.00 to $15.00 in a report released on Tuesday, Benzinga reports. The brokerage presently has a “market outperform” rating on the biotechnology company’s stock. JMP Securities’ price target indicates a potential upside of 194.12% from the stock’s current price.

Other analysts have also issued reports about the company. Needham & Company LLC reiterated a “buy” rating and set a $12.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday. HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $14.00.

BioCryst Pharmaceuticals Stock Down 3.0 %

BCRX stock opened at $5.10 on Tuesday. BioCryst Pharmaceuticals has a twelve month low of $4.03 and a twelve month high of $8.96. The stock’s 50 day moving average is $4.89 and its 200-day moving average is $5.45. The firm has a market capitalization of $1.05 billion, a PE ratio of -4.77 and a beta of 1.96.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Monday, May 6th. The biotechnology company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06. The business had revenue of $92.80 million for the quarter, compared to the consensus estimate of $85.62 million. The business’s revenue was up 34.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.28) earnings per share. On average, equities research analysts anticipate that BioCryst Pharmaceuticals will post -0.69 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of BCRX. Fifth Third Bancorp boosted its holdings in shares of BioCryst Pharmaceuticals by 17,500.0% in the third quarter. Fifth Third Bancorp now owns 3,520 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 3,500 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in BioCryst Pharmaceuticals by 96.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 4,865 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 2,388 shares in the last quarter. Quarry LP bought a new position in BioCryst Pharmaceuticals in the 4th quarter worth about $54,000. Tower Research Capital LLC TRC boosted its stake in BioCryst Pharmaceuticals by 131.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 10,420 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 5,912 shares during the period. Finally, JGP Global Gestao de Recursos Ltda. purchased a new position in BioCryst Pharmaceuticals during the 4th quarter valued at about $64,000. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.